Population
Patients with established doxorubicin cardiomyopathy
Design
Review
Authors
Loading...
High mortality once HF develops in doxorubicin cardiomyopathy warrants close surveillance; leaves open need for effective therapies.
Doxorubicin cardiomyopathy carries an approximately 50% mortality once congestive heart failure develops, with no effective treatments currently available.
Chatterjee et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: